**12. Our experience**

At Cleveland clinic we have an experience of about 150 patients, who underwent LITT for a variety of indications since 2011. At our center, we use NeuroBlate® System (Monteris Medical

Corporation, Plymouth, MN, USA) with a side firing probes (Figure 1). Regarding intra-axial tumors, we have used LITT in 30 patients with de novo GBM, 24 patients with recurrent GBM (following standard treatment), 22 patients with recurrent anaplastic tumors, upfront in 10 patients with anaplastic tumors, 24 patients with low-grade gliomas (7 upfront and 17 recurrent). We have also used this modality in 17 patients with radiation necrosis and 15 patients with metastasis. We are also participating in a multi-institutional study investigat‐ ing the role of this modality in patients with failed SRS (LAASR study). We have also utilized this therapy in patients with recurrent meningioma (*n* = 4) and schwanomma (*n* = 1, upfront) as well as epilepsy surgery (more than five cases).
